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OBJECTIVES We evaluated the effect of orally administered tranilast, N-(3,4-dimethoxycinnamoyl)
anthranilic acid, on histologic and histomorphometric changes after angioplasty or stent
implantation in pig coronary arteries.
BACKGROUND Tranilast, which has antikeloid and antiallergic properties and therefore may modulate the
fibrotic and inflammatory tissue responses to angioplasty and stenting, has been shown to
inhibit angiographic restenosis in small clinical trials. However, its effect on histomorpho-
metric changes in coronary arteries after angioplasty and stenting is unknown.
METHODS Following initial pharmacokinetic studies in two pigs to determine desirable plasma levels of
orally administered tranilast, 36 crossbred juvenile pigs were randomized to placebo or
tranilast before undergoing balloon angioplasty in both the left anterior descending and left
circumflex plus stent implantation in the right coronary artery. Oral tranilast was adminis-
tered at 3 g/day starting 3 days before coronary injury and continued for 28 days until
euthanasia. Injured vessels were harvested and sections analyzed by computer-assisted
microscopic planimetry.
RESULTS In balloon-injured vessels, tranilast was associated with a 37% reduction in neointimal area
normalized to fracture length (0.47 6 0.01 vs. 0.74 6 0.03 mm; p , 0.001) and a 23%
reduction in adventitial area normalized to vessel size (0.43 6 0.02 vs. 0.56 6 0.03; p 5
0.003). In stented arteries, neointimal area normalized to injury score was 32% lower in the
tranilast-treated group compared to control (1.94 6 0.17 vs. 2.86 6 0.29; p 5 0.01).
CONCLUSIONS In pig coronary arteries, tranilast was associated with a reduction in neointima formation and
adventitial reaction after balloon injury. In stented vessels, tranilast was associated with a
reduction in neointima formation normalized to injury score. (J Am Coll Cardiol 2000;35:
1331–7) © 2000 by the American College of Cardiology
Restenosis remains the most problematic complication of
percutaneous transluminal coronary angioplasty (PTCA)
with significant costs to the health care system (1). Stent
implantation initially appeared promising, with rates of 20%
to 30% in so-called ideal lesions (2,3), but with improve-
ment of stent technology, the indications of stenting have
broadened, with a consequent restenosis rate ranging from
15% to 60% (4,5) at six months depending on lesion
morphology and other factors. Pharmacological approaches
in humans have been largely disappointing (6). However,
recent clinical studies using oral tranilast have demonstrated
promise through a decrease in the rates of angiographic
restenosis (7).
Tranilast, N-(3,4-dimethoxycinnamoyl) anthranilic acid
(molecular weight 327 Da), has been used for the preven-
tion and treatment of keloids and hypertrophic scarring and
for the treatment of a range of allergic conditions (8,9). In
in vitro studies using vascular smooth muscle cells (SMC),
tranilast has been shown to inhibit cellular proliferation
(10,11), cellular migration (10,11), collagen synthesis
(10,11), angiotensin-II–mediated SMC contraction (12)
and to restore cytokine-induced nitric oxide production
against platelet-derived growth factor (PDGF) (13). Tra-
nilast has also been shown to inhibit collagen synthesis in
fibroblasts derived from hypertrophic tissues and keloids
(14), to suppress mast cell degranulation and histamine
release (15,16) and to suppress oxygen free radical produc-
tion by neutrophils (17,18). In in vivo studies using either
carotid or peripheral arteries of small animals (19–23),
tranilast was effective in reducing neointimal area on histo-
morphometry.
Clinical efficacy studies evaluating tranilast for restenosis
prevention have now been completed in over 700 Japanese
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male patients who underwent PTCA. In the TREAT study
(Tranilast REstenosis following Angioplasty Trial), a
double-blind, randomized, multicenter trial, tranilast
(600 mg/day for three months) reduced the angiographic
restenosis rate at three months’ post-PTCA from 46.5% to
14.7%, a relative reduction of 68%, p , 0.001 (personal
communication, Dr. H. Tamai). This result was confirmed
by the TREAT-2 study, with similar relative reduction in
the restenosis rate (personal communication, Dr. H. Ta-
mai). Tranilast was also found to decrease the angiographic
restenosis in stented lesions (personal communication, Dr.
H. Tamai) and in patients undergoing directional coronary
atherectomy (7). A large multicenter trial to investigate the
effects of tranilast on restenosis (PRESTO) in over 11,000
patients undergoing PTCA and/or stent implantation has
recently started.
Despite the clinical promise being shown by this oral
agent for restenosis prevention, few data are available about
the influence of tranilast on arterial wound healing in the
setting of coronary interventions. We therefore investigated
the effects of tranilast on histologic and histomorphometric
changes in pig coronary arteries after balloon angioplasty
and stent implantation.
METHODS
All experiments and animal care conformed to the National
Institutes of Health and American Heart Association
guidelines for the care and use of animals and were approved
by the Emory University Institutional Animal Care and Use
Committee.
Pharmacokinetic study. Because tranilast had not been
previously used in pigs we examined the pharmacokinetic
profile (Emax and t1/2) of oral tranilast in juvenile pigs before
initiating the efficacy study. A right atrial cannula was
placed in two pigs via the jugular vein on the day prior to
dosing. A first dose of either 50 to 100 mg/kg was given by
mixing with corn syrup and pig chow; the alternate dose was
given the following day. Blood samples (0, 30 min, 2, 8, and
24 h) were obtained following these single-dose oral admin-
istrations of tranilast. Plasma was separated by centrifuga-
tion, frozen, protected from light exposure and analyzed for
tranilast content (Kissei Pharmaceutical, Japan). A dose of
100 mg/kg/day resulted in a peak plasma concentration of
38.6 6 1.27 mg/ml (118 6 3.9 mmol/liter) at 2 h and a t1/2
of 8.9 h. Based on these findings and considering previous
in vitro and in vivo animal studies (10–23), tranilast was
given in the efficacy study at a dose of 1500 mg/pig twice
daily. As pigs initially weighed between 22.8 and 31.3 kg,
this corresponded to a dosing range of 95.8 to 131.6 mg/kg.
Oral treatment was started three days before coronary injury
and continued until tissue harvest. Blood samples for drug
levels and liver function tests were collected at the time of
the procedure as well as at day 28 for analysis.
Efficacy study design. Thirty-six female or castrated male
juvenile pigs (25 to 30 kg) were randomized to receive
placebo (n 5 18) or oral tranilast (n 5 18). All pigs
underwent balloon overstretch injury of the left anterior
descending (LAD) and circumflex (CX) coronary arteries,
and oversize stent implantation in the right coronary artery
(RCA) according to established methods (24,25). Briefly,
pigs were sedated with telazol (5 mg/kg IM), intubated and
ventilated with isoflurane in a mixture of 50% O2 and
50% N2O at a rate of ;30 ml/kg/min. An 8F sheath and
guiding catheter were introduced via the right femoral
artery. Acetylsalicylate (2 mg/kg), heparin (200 IU/kg), and
lidocaine (2 mg/kg) were administered intra-arterially. An-
gioplasty was performed using a 3.5-mm balloon, and a
4.0-mm balloon expandable stainless steel stent (slotted
tube stainless steel PS153; Cordis, Miami Lakes, Florida)
was implanted in the RCA after previous overstretch injury
to achieve a 1:1.2–1.3 balloon-to-artery ratio; the operator
was unaware of the treatment group assignment. Intracoro-
nary nitroglycerin (200 mg) was administered in each artery
before injury. Immediately postprocedure, angiograms were
performed to assess vessel patency; the femoral sheath was
removed, the femoral artery ligated, the skin closed and the
animal allowed to recover. Pigs were returned to routine
care including daily monitoring and drug feeding until 28
days.
Tissue processing and histomorphometry. Animals were
euthanized with a lethal dose of pentobarbital, the heart was
quickly removed and the coronary vasculature was
perfusion-fixed with 10% buffered formalin at
;100 mm Hg pressure for 15 min. The heart was then
immersed in 10% buffered formalin overnight. The balloon-
injured arterial segments were cut into 3–4-mm segments,
embedded in paraffin, sectioned to 4 mm thickness, and
stained with hematoxylin–eosin (H&E), Verhoeff–van Gie-
son’s (VVG) elastic tissue stain and Masson’s trichrome.
Injured arteries were defined as those in which there was a
complete rupture of the tunica media. Stented arteries were
embedded in methyl-butyl methacrylate and sectioned using
a low-speed saw. Serial sections spanning the injury site
were glued to acrylic slides, ground to ;100 mm thickness,
polished to optical smoothness, and stained with H&E or
VVG.
Abbreviations and Acronyms
AA 5 adventitial area
FL 5 fracture length
IA 5 neointimal area
IS 5 injury score
MIT 5 maximal intimal thickness
PDGF 5 platelet-derived growth factor
PTCA 5 percutaneous transluminal coronary
angioplasty
SMC 5 smooth muscle cell
TGF 5 transforming growth factor
VA 5 vessel area
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Computer-assisted planimetry using Image Pro Plus
(Media Cybernetics, 3.0.01.00) with external instrument
calibration at 203 magnification was used to measure
luminal area (LA), internal elastic lamina area (IELA; area
within the perimeter of the internal elastic lamina), vessel
area (VA; area within the perimeter of the external elastic
lamina), adventitial area (AA), maximal neointimal thick-
ness (MIT, determined by drawing a radial line from the
lumen border to the internal elastic lamina at the point of
maximal neointima), arc length of the medial fracture or
fracture length (FL) in ballooned arteries and injury score
(IS) in stented arteries. The IS used was an adaptation of
the scoring system described by Schwartz et al. (26), which
consisted of five grades according to the extent of stent strut
penetration into the vessel wall: Grade 0: stent strut in the
neointima but not in contact with the internal elastic lamina
(IEL); Grade 1: stent strut in the neointima and contacting
but not penetrating the IEL; Grade 2: stent strut penetrat-
ing the IEL, but not contacting the external elastic lamina
(EEL); Grade 3: stent strut penetrating the media to
contact the EEL; and Grade 4: the stent strut breaching the
EEL and contacting the adventitia. The ratios of neointimal
area/fracture length (IA/FL) and IA/IS provide normalized
values of intimal area related to the extent of vessel injury
(27). The ratio of (AA–VA)/VA refers to the extent of
adventitial reaction normalized for vessel size. The neoin-
timal area (IA) and the medial area (MA) were calculated
and their ratio was expressed by IA/MA. The histomor-
phometric parameters measured on 6 to 10 sections per
vessel were averaged and expressed as mean value 6 SEM.
Vessel sections were measured by an experienced investiga-
tor who was unaware of the treatment group assignment.
Statistical analysis. Data were expressed as mean value 6
SEM. Between-group differences were assessed using the
unpaired Student t test or Mann-Whitney rank-sum test.
Data analysis was performed using a statistical software
program (Sigma-Stat, Jandel Scientific). An alpha level of
p # 0.05 was considered to indicate a significant difference.
The interobserver variability of histomorphometric mea-
surements was found to be #10%.
RESULTS
Tranilast dosing. The initial pharmacokinetic studies re-
vealed that peak plasma concentrations were obtained at 2 h
and the t1/2 was found to be 8.9 h. Based on these findings,
tranilast was given in the efficacy study at a dose of 1500
mg/pig twice daily, resulting in a dose range of 95.8 to
131.6 mg/kg in the study. Plasma levels of tranilast in
treated pigs were 1.01 6 0.49 mmol/liter at the time of
angioplasty and 0.99 6 0.53 mmol/liter at tissue harvest
(p 5 NS); these values are about 10-fold higher than those
obtained with a single-dose administration, indicating an
accumulation in serum and/or tissue compartments with
repeated administration. Serum levels of total protein,
albumin, creatinine, transaminase, total bilirubin and lactate
dehydrogenase were within normal limits and did not differ
between the control and tranilast-treated groups.
Histology and histomorphometry. Thirty-six animals un-
derwent interventions on 108 coronary arteries; 72 arteries
were ballooned and 36 stented. There were no significant
differences in body weight between the tranilast-treated and
control groups either at angioplasty (26.9 6 0.7 vs. 26.7 6
0.7 kg) or 28 days (35.2 6 1.0 vs. 33.6 6 0.9 kg).
BALLOON-INJRED VESSELS. Balloon injury was associated
with complete medial rupture in 71 out of the 72 balloon-
injured arteries, obvious neointima formation and an in-
crease in AA, especially adjacent to the area of medial
rupture (Fig. 1). Masson’s trichrome staining revealed
abundant collagen in the neointima as well as adjacent
adventitia. The histomorphometric changes due to balloon
injury in the placebo and tranilast-treated groups are shown
in Table 1. No significant differences existed between the
treatment and control groups in either the extent of injury
(as seen by the magnitudes of the FL) or the vessel size (as
seen by the magnitudes of the VA). Compared with
placebo, tranilast was associated with a significantly smaller
IA (0.79 6 0.06 vs. 1.32 6 0.12 mm2, p , 0.001), IA
normalized to FL (0.47 6 0.01 vs. 0.74 6 0.03 mm, p ,
0.001), MIT (0.51 6 0.02 vs. 0.63 6 0.03 mm, p 5 0.009),
AA (5.61 6 0.21 vs. 6.68 6 0.26 mm2, p 5 0.004), AA
normalized to VA (0.43 6 0.02 vs. 0.56 6 0.03, p 5 0.003)
and IA/MA (0.88 6 0.09 vs. 1.77 6 0.24, p , 0.001).
STENTED VESSELS. All stents were seen to be well devel-
oped within the vessel, resulting in thinning of the media
adjacent to the stent struts (Fig. 2). In the rare vessels with
stent protrusion into the adventitia, there was evidence of
perivascular hemorrhage. Inflammatory infiltrates adjacent
to the stent struts were observed but with no discernible
differences between tranilast-treated and control groups.
The histomorphometry of the stented vessels is shown in
Table 2. No significant difference was seen in vessel size
(EELA) between tranilast-treated group and placebo. The
IS ranged between 1 and 2.4 overall and was 1.60 6 0.07 for
the treated group compared to 1.43 6 0.08 for the controls
(p 5 0.14). The neointimal area (IA) normalized to injury
score (IA/IS) was significantly lower in the tranilast-treated
group compared to controls (1.94 6 0.17 vs. 2.86 6 0.29;
p 5 0.01). There was a strong trend toward reduction in
absolute IA in the tranilast-treated group compared to
controls (3.13 6 0.30 vs. 4.11 6 0.45, p 5 0.07). There was
also a significant difference in the medial area between the
tranilast-treated group and placebo (p 5 0.05) and a
significant difference in IA/MA between the two groups
(1.16 6 0.14 vs. 1.73 6 0.13, p 5 0.002).
DISCUSSION
The major findings of this study are that tranilast signifi-
cantly reduced neointima formation as well as adventitial
reaction after balloon injury at four weeks in pig coronary
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arteries; in stented vessels, tranilast significantly reduced
neointima formation normalized to IS. To our knowledge,
this is the first study to demonstrate these effects. These data
as well as preliminary clinical trials (7) suggest the potential
for using tranilast as a clinical therapeutic strategy in
coronary restenosis prevention.
In balloon-injured vessels, the significant reduction
observed in neointima formation, coupled with the lack
Figure 1. Light microscopy of VVG-stained sections of pig coronary arteries harvested four weeks after overstretch balloon angioplasty.
Top panels are from control; bottom panels from tranilast-treated animal. Left panels are 403 instrument magnification; right panels
2003. Note decreased neointima formation in artery of tranilast-treated pig despite balloon injury similar to control. L 5 lumen; M 5
tunica media; A 5 tunica adventitia; N 5 neointima.
Table 1. The Effect of Tranilast on the Vessel Response to Balloon Injury
Control
Group
Tranilast
Group
p
Value
%
Change
LA (mm2) 2.10 6 0.11 2.23 6 0.12 0.37 26.2
VA (mm2) 4.33 6 0.19 3.96 6 0.16 0.37 8.5
FL (mm) 1.75 6 0.10 1.65 6 0.10 0.29 5.7
AA (mm2) 6.68 6 0.26 5.61 6 0.21 0.004 16.0
MIT (mm) 0.63 6 0.03 0.51 6 0.02 0.009 19.0
LA/VA 0.48 6 0.01 0.55 6 0.01 ,0.001 214.6
(AA-VA)/VA 0.56 6 0.03 0.43 6 0.02 0.003 23.2
IA (mm2) 1.32 6 0.12 0.79 6 0.06 ,0.001 40.2
MA (mm2) 0.91 6 0.06 0.94 6 0.04 0.71 23.3
IA/FL (mm) 0.74 6 0.03 0.47 6 0.01 ,0.001 36.5
IA/MA 1.77 6 0.24 0.88 6 0.09 ,0.001 50.3
LA 5 luminal area; VA 5 vessel area; FL 5 fracture length; AA 5 adventitial area; MIT 5 maximal intimal thickness; IA 5
neointimal area; MA 5 medial area. Data are presented as mean value 6 SEM.
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of increase in the vessel area, suggests that tranilast may
reduce restenosis by an inhibitory effect on neointima
formation rather than by promoting chronic positive
vessel remodeling. This lack of effect on vessel remodel-
ing (i.e., alteration of EELA) occurred despite significant
reduction in the adventitial reaction as determined by
cross-sectional area, observed in the tranilast-treated
group at four weeks.
In theory, the reduction in neointima formation due to
tranilast could have resulted from an inhibition in cellular
proliferation or a reduction in net extracellular matrix
content. Several mechanisms of tranilast’s action that might
Figure 2. Light microscopy of H&E-stained sections of pig coronary arteries harvested four weeks after stenting. Top panels are from
control; bottom panels from tranilast-treated animal. Left panels are 203 instrument magnification; right panels 2003. Note similar
neointima formation in artery of tranilast-treated pig despite stent injury greater than control (arrows in panel 2c). L 5 lumen; M 5
tunica media; A 5 tunica adventitia; N 5 neointima.
Table 2. The Effect of Tranilast on the Vessel Response to Stent Injury
Control
Group
Tranilast
Group
p
Value
%
Change
LA (mm2) 4.51 6 0.41 5.49 6 0.38 0.087 221.7
IELA (mm2) 8.62 6 0.54 8.62 6 0.30 1.00 0
EELA (mm2) 11.03 6 0.66 11.61 6 0.32 0.86 25.2
MIT (mm) 0.86 6 0.09 0.71 6 0.07 0.24 17.4
IA (mm2) 4.11 6 0.45 3.13 6 0.30 0.07 23.8
IS 1.43 6 0.08 1.6 6 0.07 0.14 211.8
MA (mm2) 2.41 6 0.22 2.99 6 0.24 0.05 224.0
IA/IS 2.86 6 0.29 1.94 6 0.17 0.01 32.2
IA/MA 1.73 6 0.13 1.16 6 0.14 0.002 32.9
LA 5 luminal area; IELA 5 internal elastic lamina area; EELA 5 external elastic lamina area; MIT 5 maximal intimal
thickness; IA 5 neointimal area; IS 5 injury score; MA 5 medial area. Data are presented as mean value 6 SEM.
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influence neointima formation have been elucidated. Tra-
nilast inhibits spontaneous collagen synthesis and trans-
forming growth factor-b1 (TGF-b1)-induced collagen and
glycosaminoglycan synthesis, as well as PDGF-induced
migration and proliferation of vascular SMC (10). The
mechanism of the inhibitory action on PDGF-BB–induced
proliferation is due to S-phase blockade; furthermore, tra-
nilast suppresses the expression of the proto-oncogene
c-myc (28). The role of c-myc in abnormal proliferation of
vascular SMC after PTCA has recently received attention
because its mRNA levels are enhanced after injury (29).
Additionally, the antisense suppression of c-myc mRNA has
an inhibitory effect on vascular SMC proliferation following
balloon angioplasty (30). Thus, tranilast could suppress early
stages of neointima formation by inhibiting c-myc expres-
sion in arterial cells.
Additionally, prior studies have suggested that adventitial
fibroblasts may contribute to neointima formation as well as
remodeling (31,32). Phenotypic transformation of adventi-
tial cells into myofibroblasts may chronically constrict the
injured vessel and contribute to the process of arterial
remodeling and late lumen loss after angioplasty (31). The
proliferation of adventitial fibroblasts and modulation of
their phenotype to myofibroblasts are all associated with the
development of a thickened adventitia that eventually results
in vascular remodeling and shrinkage of the vessel in a
process analogous to scar contraction (31–33). Upregulation
of TGF-b1 expression may provide a signal to transform
adventitial fibroblasts into myofibroblasts (34). Tranilast is
known to inhibit TGF-b1–induced collagen and glycos-
aminoglycan synthesis (10) and to inhibit the TGF-b–
independent phenotypic alterations of fibroblasts to
myofibroblast-like cells and their proliferation (35). Our
results demonstrate that tranilast suppressed neointima
formation and adventitial reaction; this may be due in part
to reduction in cellular proliferation as well as extracellular
matrix deposition.
In-stent restenosis is a vexing problem in interventional
cardiology. Stents have decreased the restenosis rate by
preventing early elastic recoil and late negative arterial
remodeling, but profound neointima formation is the main
cause of restenosis. Although statistically significant, the
effects of tranilast in the stented group compared to the
balloon group were less pronounced. In the tranilast-treated
group, IA/IS was reduced by 32%. It has been suggested
that pharmacological approaches may not be as effective in
reducing stent versus balloon-induced neointima formation
(36). Part of the reasoning behind this is that the stent
prosthesis induces a foreign-body response in which both
inflammation and continued low-level cell proliferation play
important roles. Additionally, the thrombus burden in
stented arteries may be more substantial than in balloon
angioplasty (37). Despite these concerns oral administration
of tranilast was associated with substantial reduction of
neointima in stented arteries.
There has been concern about the potential side effects
of tranilast, including organ and systemic toxicity involv-
ing the kidneys and liver. In our study we examined
serum markers of kidney and liver function and did not
observe an adverse effect of tranilast. Furthermore, the
tranilast-treated pigs did not demonstrate any clinical
symptoms suggestive of adverse cardiopulmonary or gas-
trointestinal sequelae. Shioda (8) and Okuda et al. (9)
studied the antiallergic properties of tranilast in children
and adults and found no serious side effects. In a study
that demonstrated reduction of restenosis after coronary
atherectomy, liver dysfunction or abdominal discomfort
was present in 5 of 45 patients (7); the large multicenter
investigation now underway (PRESTO) should help
elucidate whether tranilast can be given safely and effec-
tively for restenosis prevention. A final potential compli-
cation with the use of tranilast might be that, owing to its
property to limit collagen synthesis and fibroblast prolif-
eration, a severely limited fibrotic tissue reaction could
compromise the adherence of the stent to the artery wall;
however, our results indicate that, although neointima
was reduced, a sufficient fibrotic response was present to
support tissue incorporation of the stents, as documented
by VVG-stained stent sections showing fibrous neoin-
tima enveloping the stent struts in all samples.
Study limitations. Our results on the effect of tranilast
after balloon injury and stenting should be interpreted
cautiously and regarded as preliminary as they only reflect an
interim response at four weeks. Studies evaluating the effect
of tranilast on histomorphometric changes in the vessel wall
at later time points have not been undertaken. The obvious
possibility of interspecies variability in the biological re-
sponse precludes direct extrapolation to humans. Further-
more, although our study demonstrated reduction of neo-
intima and neoadventitia by tranilast, the putative
mechanisms of these effects are as yet unknown.
Conclusions. Oral administration of tranilast inhibited
neointima formation and adventitial reaction in balloon-
injured pig coronary arteries at four weeks. In stented
coronary arteries tranilast was associated with a significant
reduction in neointimal area normalized to the extent of
injury, and it showed a strong trend in reducing absolute
neointimal area. These results could explain the beneficial
effects seen with the initial clinical studies evaluating tra-
nilast in restenosis prevention.
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